Close menu

December 23rd, 2022 | 08:00 CET

BioNxt Solutions, MorphoSys, BioNTech - Innovations and scaling potential for the portfolio

  • Biotechnology
Photo credits:

Around the world, patients are used to swallowing medicines in pill form. Sales of oral, fixed-dose drugs alone accounted for a whopping 23.8% of the global pharmaceutical drug delivery market in 2021. That is reason enough for Canadian biotech company BioNxt Solutions to further expand its strategic pole position. BioNxt Solutions secures further rights to a unique platform technology in this segment. Caution is currently the order of the day for MorphoSys. Analysts downgrade the target price from EUR 16 to EUR 12 after a disappointing Q3. BioNTech, on the other hand, can expand its dominance. The Mainz-based company is scaling up in the Asia-Pacific region with new production sites.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: BioNxt Solutions Inc. | CA0909741062 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNxt Solutions - Acquisition of additional technology platform for strategic expansion

    Since the Covid pandemic, investors know how intensively the development speed of a vaccine can affect company profits. Pfizer, Moderna and BioNTech have proven it: Digitization has reached the pharmaceutical industry. Where research and development cycles of about 10 years usually dominate, platform technologies now provide an opportunity to drive product commercialization rapidly.

    The Canadian biotech company BioNxt (formerly XPhyto) is excellently positioned with its portfolio. Its business model includes point-of-care diagnostics, innovative drug delivery methods, and the mental health space with breakthrough compounds.

    The faster the active ingredients of drugs enter the bloodstream and take effect, the sooner patients are helped. Orally administered drugs in particular are prescribed most frequently worldwide. Revenue from the sale of oral, fixed-dose drugs accounted for 23.8% of the global pharmaceutical drug delivery market in 2021. BioNxt (ISIN CA0909741062) is soon acquiring additional rights to a platform with a novel coating technology for solid oral dosage forms. "We are delighted to add another drug delivery platform to the technology portfolio," said Hugh Rogers, CEO & Director of BioNxt. "This novel coating system could significantly improve oral drug delivery in the form of tablets and capsules by providing more precise and predictable dosing. We see a wide range of potential applications, from dietary supplements and over-the-counter medications to prescription drugs and psychedelic substances."

    The global oral solid dosage market was valued at USD 524.6 billion in 2021 and is expected to reach USD 1.03 trillion by the end of 2032, growing rapidly at a CAGR of 6.4% during the study period 2022-2032, according to Fact.MR Research & Consulting.

    MorphoSys - Target Price falls from EUR 16 to EUR 12, CFO resigns

    The German company MorphoSys (ISIN DE0006632003) is currently experiencing stormy times. Goldman Sachs downgrades the Company from "neutral" to "sell". Their analysts forecast a price target of EUR 12.00. The reason given is the disappointing third quarter, increased competition and little chance of profit in the coming twelve months. Over the current year, the MorphoSys share fell by a whopping 62.82%.

    In November, the Company suffered a major setback as an Alzheimer's drug candidate they developed in collaboration with Roche failed to meet its goal of slowing the progression of the memory-robbing disease in two separate trials.

    Now, in addition, the chief financial officer is leaving the Company for personal reasons in March 2023. Sung Lee joined MorphoSys in Germany in February 2021. Through the acquisition of Constellation Pharmaceuticals, Sung helped build the Company's future growth and strengthened the pipeline with the first-line drug for myelofibrosis, a malignant bone marrow disease.

    "The last two years have been an exciting time for MorphoSys as we sharpened the Company's strategy and accelerated our goal to become a leader in hematology oncology," said Sung Lee, Chief Financial Officer of MorphoSys. MorphoSys is committed to improving the lives of cancer patients. Its departments are located in Planegg, near Munich, Germany, and in Boston, MA, USA.

    BioNTech - On track for growth in the Asia-Pacific region

    A competitor on the radar in cancer therapy is BioNTech (ISIN US09075V1026), a biotech company based in Mainz, Germany. The Company will accelerate and expand the clinical development of its cancer immunotherapy pipeline in Asia-Pacific by increasing its manufacturing capacity in the region.

    The first regional clinical trial sites will initially evaluate head and neck cancer candidates in Taiwan for novel cancer immunotherapies. BNT113 is expected to be the first of a "potential wave of novel cancer immunotherapies." The German company is bringing Taiwan's YongLin Healthcare Foundation and Retain Biotech AG on board to further develop plans for genomic medicine in oncology.

    Last month, the parties signed a memorandum of understanding to develop this medical direction further. The YongLin Healthcare Foundation is funding this organization, which is involved in precision medicine and cell therapy. The Australian site in Melbourne is also earmarked as a launching point to develop the Pacific region.

    In addition, BioNTech announced plans to establish an end-to-end clinical-scale mRNA production facility in Melbourne based on the BioNTainer solution to provide access to mRNA technology and foster research collaborations in the Asia-Pacific region. BioNTech has already established subsidiaries in Singapore, Shanghai and Melbourne. In addition, a representative office has been registered in Taipei, which is expected to become part of the Company's global network as regional innovation centers. These locations are expected to create hundreds of jobs in various functions by 2024.

    The rally for the best possible digitization of the production process of pharmaceuticals and the associated rapid commercialization currently seems to be leading with BioNxt Solutions. The Company focuses on platform technology for oral drugs. MorphoSys, with its focus on oncology, has to be patient. After the setback with Roche, the CFO is now leaving the Company, and analysts are lowering the target price to EUR 12. BioNTech, on the other hand, is expanding its business in the Asia-Pacific region through collaborations and new production sites. The scaling opportunities of oral pharmaceuticals, oncology and the provision of production sites for mRNA active ingredients seem unlimited.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.


    Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST

    Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments

    • Sustainability
    • Pharma
    • Biotechnology
    • renewableenergies
    • CarbonCredits

    Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.


    Commented by André Will-Laudien on July 11th, 2024 | 06:45 CEST

    Mega rally on the cards - 500% plus is likely too low an estimate! Evotec, Desert Gold, Cogia, VCI Global, and Lufthansa

    • Mining
    • Gold
    • Commodities
    • Biotechnology
    • airline

    The stock market keeps rising and rising - this much is revealed by the ever-new highs of prominent indices such as the NASDAQ 100, S&P 500, or the Nikkei index. However, a closer look reveals some inconsistencies. For example, only 6% of all traded stocks are currently reaching new highs, while over 70% of all listed stocks have fallen since the beginning of the year. In short, global liquidity is aggregated in just a few blockbuster stocks, with the rest being left behind. Such bubbles already occurred in 1999, 2007, and 2015, followed by a 25% to 50% correction. When exactly this will happen, no one knows, but the party is likely to continue for a while due to high liquidity. Gold and silver are in the process of forming interesting breakout formations. Now is the time to pick the cherries!